Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Fortress Biotech files to sell 2.1M shares of common stock for holders  17:17
11/09/20
11/09
17:17
11/09/20
17:17
FBIO

Fortress Biotech

$2.34 /

+0.025 (+1.08%)

 
ShowHide Related Items >><<
FBIO Fortress Biotech
$2.34 /

+0.025 (+1.08%)

FBIO Fortress Biotech
$2.34 /

+0.025 (+1.08%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.34 /

+0.025 (+1.08%)

Earnings
Fortress Biotech reports Q3 EPS (15c), consensus (22c) » 16:50
11/09/20
11/09
16:50
11/09/20
16:50
FBIO

Fortress Biotech

$2.34 /

+0.025 (+1.08%)

Reports Q3 revenue…

Reports Q3 revenue $9.48M, consensus $11.32M. "The third quarter was highlighted by multiple transactions that strengthened our balance sheet. First, we received gross proceeds of approximately $12 million through our Series A perpetual preferred stock offering. Later in the quarter, we signed a $60 million refinancing agreement with Oaktree Capital Management. Moreover, we demonstrated significant top-line growth, as our net product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million," said Lindsay Rosenwald, Fortress' chairman, president and CEO. "Based on the potential for multiple additional commercial product opportunities over the next few years, Fortress is well-positioned to drive further meaningful growth in our business."

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.34 /

+0.025 (+1.08%)

FBIO Fortress Biotech
$2.34 /

+0.025 (+1.08%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.34 /

+0.025 (+1.08%)

Conference/Events
Fortress Biotech management to meet virtually with B. Riley Securities » 04:55
10/27/20
10/27
04:55
10/27/20
04:55
FBIO

Fortress Biotech

$2.53 /

-0.13 (-4.89%)

Virtual Meeting to be…

Virtual Meeting to be held on October 27 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.53 /

-0.13 (-4.89%)

FBIO Fortress Biotech
$2.53 /

-0.13 (-4.89%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.53 /

-0.13 (-4.89%)

Over a month ago
Conference/Events
Fortress Biotech management to meet virtually with B. Riley Securities » 04:55
10/22/20
10/22
04:55
10/22/20
04:55
FBIO

Fortress Biotech

$2.56 /

-0.08 (-3.03%)

Virtual Meeting to be…

Virtual Meeting to be held on October 22 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.56 /

-0.08 (-3.03%)

FBIO Fortress Biotech
$2.56 /

-0.08 (-3.03%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.56 /

-0.08 (-3.03%)

Conference/Events
Fortress Biotech management to participate in a webinar hosted by Roth Capital » 12:25
10/21/20
10/21
12:25
10/21/20
12:25
FBIO

Fortress Biotech

$2.55 /

-0.095 (-3.60%)

Roth Capital…

Roth Capital Pharmaceuticals Analyst Henry holds a webinar with the management of Fortress Biotech subsidiary, Journey Medical Corporation on October 21 at 1 pm.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.55 /

-0.095 (-3.60%)

FBIO Fortress Biotech
$2.55 /

-0.095 (-3.60%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.55 /

-0.095 (-3.60%)

Conference/Events
Fortress Biotech management to participate in a webinar hosted by Roth Capital » 04:55
10/21/20
10/21
04:55
10/21/20
04:55
FBIO

Fortress Biotech

$2.64 /

+0.01 (+0.38%)

Roth Capital…

Roth Capital Pharmaceuticals Analyst Henry holds a webinar with the management of Fortress Biotech subsidiary, Journey Medical Corporation on October 21 at 1 pm.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.64 /

+0.01 (+0.38%)

FBIO Fortress Biotech
$2.64 /

+0.01 (+0.38%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.64 /

+0.01 (+0.38%)

Conference/Events
Fortress Biotech management to meet virtually with B. Riley Securities » 12:13
10/20/20
10/20
12:13
10/20/20
12:13
FBIO

Fortress Biotech

$2.58 /

-0.05 (-1.90%)

Virtual Meeting to be…

Virtual Meeting to be held on October 27 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.58 /

-0.05 (-1.90%)

FBIO Fortress Biotech
$2.58 /

-0.05 (-1.90%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.58 /

-0.05 (-1.90%)

Conference/Events
Fortress Biotech management to meet virtually with B. Riley Securities » 11:43
10/20/20
10/20
11:43
10/20/20
11:43
FBIO

Fortress Biotech

$2.55 /

-0.08 (-3.04%)

Virtual Meeting to be…

Virtual Meeting to be held on October 22 hosted by B. Riley Securities.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.55 /

-0.08 (-3.04%)

FBIO Fortress Biotech
$2.55 /

-0.08 (-3.04%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.55 /

-0.08 (-3.04%)

Conference/Events
Fortress Biotech management to participate in a webinar hosted by Roth Capital » 11:04
10/20/20
10/20
11:04
10/20/20
11:04
FBIO

Fortress Biotech

$2.54 /

-0.09 (-3.42%)

Roth Capital…

Roth Capital Pharmaceuticals Analyst Henry holds a webinar with the management of Fortress Biotech subsidiary, Journey Medical Corporation on October 21 at 1 pm.

ShowHide Related Items >><<
FBIO Fortress Biotech
$2.54 /

-0.09 (-3.42%)

FBIO Fortress Biotech
$2.54 /

-0.09 (-3.42%)

10/13/20 B. Riley Securities
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
FBIO Fortress Biotech
$2.54 /

-0.09 (-3.42%)

Recommendations
Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities » 08:13
10/13/20
10/13
08:13
10/13/20
08:13
FBIO

Fortress Biotech

$3.16 /

-1.02 (-24.40%)

B. Riley Securities…

B. Riley Securities analyst Mayank Mamtani views the selloff in Fortress Biotech (FBIO) after the company announced yesterday that its publicly traded subsidiary, Avenue Therapeutics (ATXI), received a complete response letter from the FDA relating to IV tramadol, the only intravenous schedule IV opioid for management of post-operative pain, as overblown. No requirement of additional clinical trial data is specified in the CRL, which makes the upcoming Type A meeting an important catalyst, Mamtani tells investors in a research note. The analyst keeps a Buy rating on Fortress Biotech with an $8 price target.

ShowHide Related Items >><<
FBIO Fortress Biotech
$3.16 /

-1.02 (-24.40%)

FBIO Fortress Biotech
$3.16 /

-1.02 (-24.40%)

10/12/20 H.C. Wainwright
H.C. Wainwright cuts Fortress Biotech target to $10 after Avenue's 'bizarre' CRL
10/02/20 Benchmark
Fortress Biotech initiated with a Buy at Benchmark
08/21/20 B. Riley Securities
Fortress Biotech price target raised to $8 from $6 at B. Riley FBR
04/13/20 B. Riley Securities
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
FBIO Fortress Biotech
$3.16 /

-1.02 (-24.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.